72 results
20-F/A
2018 FY
ENLV
Enlivex Therapeutics Ltd
31 Jan 20
Annual report (foreign) (amended)
4:31pm
, 2019 (the “Closing Date”), Bioblast Pharma Ltd., a company organized under the laws of the State of Israel (“Bioblast”), and Enlivex Therapeutics R&D Ltd … ., a company organized under the laws of the State of Israel (f/k/a Enlivex Therapeutics Ltd., “Enlivex R&D”), consummated a merger transaction
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
in salaries as a result of hiring additional R&D personnel and certain pay increases for existing R&D personnel .
General and administrative expenses … manufactured and inventoried, as well as from an increase in salaries as a result of hiring additional R&D personnel and certain pay increases for existing R
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
18 May 20
Condensed Consolidated Financial Statements
4:30pm
transaction between the Parent and Enlivex Therapeutics R&D Ltd., (“Enlivex R&D”, formerly known as Enlivex Therapeutics Ltd.), pursuant to which … Enlivex R&D merged with Treblast Ltd. (a subsidiary of the Parent) with Enlivex R&D surviving the merger (the “Merger”), the Parent changed its name
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
of hiring additional R&D personnel and certain pay increases for existing R&D personnel.
General and administrative expenses were $1.5 million … of Allocetra TM doses that were manufactured and inventoried, as well as from an increase in salaries as a result of hiring additional R&D personnel
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
(the “Subsidiary”).
On March 26, 2019, upon consummation of a merger transaction between the Parent and Enlivex Therapeutics R&D Ltd., (“Enlivex R&D”, formerly … known as Enlivex Therapeutics Ltd.), whereby Enlivex R&D merged with Treblast Ltd. (a subsidiary of the Parent) with Enlivex R&D remaining
6-K
EX-99.1
iad72wmhud0quw 36dx3
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
ybxacme2c cb2sx
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
t9ub4
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
424B5
ke7 uf8y3md91rs
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
dgoyo1ann6f5yfxsq9b
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
yi30r94u5d nmvpfs
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
F-3
gl8tg a98lcmxd
28 Jun 19
Shelf registration (foreign)
9:48am
6-K
EX-99.2
iwglm
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
44l j7rrfbddulhwa
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K
EX-99.1
w3qml8xxn69iyp1vt wn
27 May 22
Condensed Consolidated Financial Statements
4:39pm
424B5
1gr2 92mhw6
9 Feb 21
Prospectus supplement for primary offering
4:56pm
F-3
EX-23.1
ol01w
28 Jun 19
Shelf registration (foreign)
9:48am
6-K
EX-99.2
9ymnzomnnm5
18 May 20
Condensed Consolidated Financial Statements
4:30pm